Assessing pneumococcal meningitis association with viral respiratory infections and antibiotics: insights from
Lulla Opatowski1, Emmanuelle Varon, Claire Dupont
1Unité de Pharmaco-épidémiologie et Maladies Infectieuses PhEMI, Institut Pasteur, 75015 Paris, France. lulla.opatowski@pasteur.fr
Abstract:
Pneumococcus is an important human pathogen, highly antibiotic resistant and a major cause of bacterial meningitis worldwide. Better prevention requires understanding the drivers of pneumococcal infection incidence and antibiotic susceptibility. Although respiratory viruses (including influenza) have been suggested to influence pneumococcal infections, the underlying mechanisms are still unknown, and viruses are rarely considered when studying pneumococcus epidemiology. Here, we propose a novel mathematical model to examine hypothetical relationships between Streptococcus pneumoniae meningitis incidence (SPMI), acute viral respiratory infections (AVRIs) and antibiotic exposure. French time series of SPMI, AVRI and penicillin consumption over 2001-2004 are analysed and used to assess four distinct virus-bacteria interaction submodels, ascribing the interaction on pneumococcus transmissibility and/or pathogenicity. The statistical analysis reveals strong associations between time series: SPMI increases shortly after AVRI incidence and decreases overall as the antibiotic-prescription rate rises. Model simulations require a combined impact of AVRI on both pneumococcal transmissibility (up to 1.3-fold increase at the population level) and pathogenicity (up to threefold increase) to reproduce the data accurately, along with diminished epidemic fitness of resistant pneumococcal strains causing meningitis (0.97 (0.96-0.97)). Overall, our findings suggest that AVRI and antibiotics strongly influence SPMI trends. Consequently, vaccination protecting against respiratory virus could have unexpected benefits to limit invasive pneumococcal infections.
Insights
Respiratory viruses and antibiotic use significantly impact Streptococcus pneumoniae meningitis incidence. Preventing viral infections may reduce invasive pneumococcal disease.
Area of Science:
- Epidemiology
- Mathematical Modeling
- Infectious Disease Dynamics
Background:
- Pneumococcus is a major cause of antibiotic-resistant bacterial meningitis globally.
- Understanding factors influencing pneumococcal infection and antibiotic susceptibility is crucial for prevention.
- The role of respiratory viruses in pneumococcal epidemiology is poorly understood.
Purpose of the Study:
- To investigate the relationship between Streptococcus pneumoniae meningitis incidence (SPMI), acute viral respiratory infections (AVRIs), and antibiotic exposure.
- To develop and analyze a mathematical model for virus-bacteria interactions.
- To assess the impact of AVRIs on pneumococcal transmissibility and pathogenicity.
Main Methods:
- Analysis of French time series data for SPMI, AVRI, and penicillin consumption (2001-2004).
- Development of four distinct virus-bacteria interaction submodels.
- Statistical analysis and model simulations to evaluate hypothetical relationships.
Main Results:
- SPMI showed a significant increase following AVRI incidence.
- Higher antibiotic prescription rates correlated with decreased SPMI.
- Model simulations indicated AVRIs increase pneumococcal transmissibility (up to 1.3-fold) and pathogenicity (up to threefold).
- Resistant pneumococcal strains causing meningitis exhibited diminished epidemic fitness (0.97).
Conclusions:
- AVRIs and antibiotic use are strong drivers of SPMI trends.
- Vaccination against respiratory viruses may offer indirect benefits in reducing invasive pneumococcal infections.
- Mathematical modeling provides insights into complex pathogen dynamics.
Related Concept Videos
Bacterial Meningitis II: Pathophysiology
Viral Meningitis
Pneumonia III: Complications and Assessment
Bacterial Meningitis I: Introduction
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia II: Pathophysiology

